scispace - formally typeset
Open AccessJournal ArticleDOI

The Prevalence of Symptoms in 24,410 Adults Infected by the Novel Coronavirus (SARS-CoV-2;COVID-19): A Systematic Review and Meta-Analysis of 148 Studies from 9 Countries

Reads0
Chats0
TLDR
It is confirmed that fever and cough are the most prevalent symptoms of adults infected by SARS-CoV-2, however, there is a large proportion of infected adults which symptoms-alone do not identify.
Abstract
Background To limit the spread of SARS-CoV-2, an evidence-based understanding of the symptoms is critical to inform guidelines for quarantining and testing. The most common features are purported to be fever and a new persistent cough, although the global prevalence of these symptoms remains unclear. The aim of this systematic review is to determine the prevalence of symptoms associated with COVID-19 worldwide. Methods We searched PubMed, Embase, CINAHL, AMED, medRxiv and bioRxiv on 5th April 2020 for studies of adults (>16 years) with laboratory test confirmed COVID-19. No language or publication status restrictions were applied. Data were independently extracted by two review authors into standardised forms. All datapoints were independently checked by three other review authors. A random-effects model for pooling of binomial data was applied to estimate the prevalence of symptoms, subgrouping estimates by country. I2 was used to assess inter-study heterogeneity. Results Of 851 unique citations, 148 articles were included which comprised 24,410 adults with confirmed COVID-19 from 9 countries. The most prevalent symptoms were fever (78% [95% CI 75%-81%]; 138 studies, 21,701 patients; I2 94%), a cough (57% [95% CI 54%-60%]; 138 studies, 21,682 patients; I2 94%) and fatigue (31% [95% CI 27%-35%]; 78 studies, 13,385 patients; I2 95%). Overall, 19% of hospitalised patients required non-invasive ventilation (44 studies, 6,513 patients), 17% required intensive care (33 studies, 7504 patients), 9% required invasive ventilation (45 studies, 6933 patients) and 2% required extra-corporeal membrane oxygenation (12 studies, 1,486 patients). The mortality rate was 7% (73 studies, 10,402 patients). Conclusions We confirm that fever and cough are the most prevalent symptoms of adults infected by SARS-CoV-2. However, there is a large proportion of infected adults which symptoms-alone do not identify.

read more

Content maybe subject to copyright    Report

Citations
More filters
Posted Content

COVID-19 Generated Changes to Planning and Development Controls in South Australia (preprint)

TL;DR: Nearly 50% COVID-19 patients could not reach obvious clinical and radiological remission within 10 days after hospitalization, and the patients with male sex, anorexia and no fever on admission predicted poor efficacy.
Journal ArticleDOI

International consensus statement on allergy and rhinology: rhinosinusitis 2021

Richard R. Orlandi, +90 more
TL;DR: The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in the understanding and treatment of rhinologic disease.
Journal ArticleDOI

Post-COVID-19 syndrome among symptomatic COVID-19 patients: A prospective cohort study in a tertiary care center of Bangladesh.

TL;DR: In this paper, the authors conducted a prospective cohort study to determine the incidence, association, and risk factors associated with development of the post-coronavirus disease (COVID-19) syndrome.
Journal ArticleDOI

Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection.

TL;DR: Current evidence is critically examined whether and how the SARS-CoV-2 virus can follow a route from the olfactory epithelium in the nose to the brain to achieve brain infection and the prospects for using the smell and taste dysfunctions seen in COVID-19 as an early and rapid diagnostic screening tool are discussed.
References
More filters
Posted ContentDOI

Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support

TL;DR: Preliminary data are presented to inform the medical community of the potential role of siltuximab in treating patients with ARDS secondary to SARS-CoV-2 infection, and a cohort study with patients treated with standard therapy in this hospital is ongoing, and will report the 30-day mortality rates upon completion.
Journal ArticleDOI

Duration and quality of the peer review process: the author's perspective.

TL;DR: Qualitative information provided by the authors indicates that editors can enhance author satisfaction by taking an independent position vis-à-vis reviewers and by communicating well with authors.
Posted ContentDOI

Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial

TL;DR: Assessment of the efficacy and safety of meplazumab, a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia found it efficiently improved the recovery of patients with SARS-CoV-2 pneumonia with a favorable safety profile.
Posted ContentDOI

COVID-19 in a Designated Infectious Diseases HospitalOutside Hubei Province,China

TL;DR: In a designated hospital outside the Hubei Province, COVID-19 patients were mainly characterized by mild symptoms and could be effectively manage by properly using the existing hospital system.
Related Papers (5)